UCB%20Group

1
UCB Group 29th July, 2003 2003 First Half-Year
Result Georges Jacobs Chairman of the Executive
Committee
2
Sectorial Breakdown
UCB Group
H1 2002 H1 2003
(in EUR million)
At constant exchange rate
In
Total Turnover 1,325 1,512 14 25
Pharma 780 739 Surface
Specialties 545 773 - of which Films
202 186
Total Ordinary Profit 266 228 -14 0
Pharma 242 193 Surface
Specialties 20 31 - of which Films
-10 - Non sectorial 4 4
Exceptional -3 -31 Taxation -81 -61
Net Profit after Taxation 182 136 -25
3
UCB Pharma
Pharma
At constant exchange rate
H1-2002 H1-2003
(in EUR million)
Turnover 780 739 818
19
30
Others
Neurology
51
Allergy
4
UCB Pharma
Pharma
H1-2002 H1-2003
At constant exchange rate
(in EUR million)

• Decrease Zyrtec turnover in Europe
• Unfavourable net exchange variances amounting to
  37 million
• Compensation of the cancellation of the Ditropan
  XL agreement ( 23 million) booked during first
  half of 2002

Ordinary profit 242 193 230
5
First Half-Year 2003 Allergy Franchise Global
In-Market Turnover EUR 860 million ()
Pharma

• USA Sharp increase despite decrease of overall
  Rx market
• EUROPE Zyrtec decreases due to generic
  competition while Xyzal more than doubled its
  turnover
• JAPAN Market share has decreased from 17 to 15

(in EUR million)
H1-2002 H1-2003
in local currency
In
USA 582 574
21 Europe 212 180 - 15 Japan 84 79
6 R. of W. 30 28 - 8
Total incl. licencees 908 860 - 5
Pfizer royalties 72 71 21
() UCB consolidated turnover in Allergy is 374
million (USA 127 million EU 146 million
Japan 73 million ROW 28 million)
6
Keppra Turnover First Half-Year 2003 EUR 135
million
Pharma

• Keppra is the first choice in add-on therapy
  among new AEDs in the US
• Most succesful launch in key markets vs. existing
  new AEDs

(in EUR million)
H1-2002 H1-2003
in local currency
In
USA 66 90 66 Europe 28
45 61 R. of W. 0.8 1 - Total
Turnover 95 135 43
7
Research Development
Pharma
I
II
III
Filing
Pre-Clinical
IV
Allergy/Asthma
Xyzal
Efletirizine
ucb 35440
Allergic Asthma and inflammatory respiratory
diseases
Multiple compounds in preclinical stage
CNS
Keppra
Line extension Paediatric, Primary Generalized
Seizures, Monotherapy New Indications
Exploratory Trials New Formulations oral
solution, IV
ucb 34714
Acute pain, Neuro-degenerative diseases,
Epilepsy related disorders
Multiple compounds in preclinical stage
In progress
Completed
8
Surface Specialties

• Total turnover negatively affected by 67
  million due to dollar depreciation
• Acquired Solutia activities amounted to 262
  million in turnover
• Volumes remain good but pressure on margins
• Films break-even

At constant exchange rate
H1-2002 H1-2003
(in EUR million)
Turnover 545 773 840 - of which
Films 202 186 208 Ordinary profit 20 31 33 - of
which Films -10 - -
9
Technical Resins
32
59
Films Adhesives
Coating Resins Additives
9
Outlook and Challenges for 2003
UCB Group

• Pharma
• Confidence for Zyrtec in the US
• Increase Xyzal sales in Europe
• Increase sales and marketing for Zyrtec in Japan
• Optimize RD efforts
• Reap benefits of business development
• Surface Specialties
• Integrate the new structure
• Benefit from first synergies

10
UCB Group 29th July, 2003 2003 First Half-Year
Result Georges Jacobs Chairman of the Executive
Committee